Buchanan Ingersoll Disqualified From Ritalin Suit

Law360, New York (July 30, 2008, 12:00 AM EDT) -- After escaping sanctions in the patent battle over a generic version of Ritalin LA, Celgene Corp. has won a bid to have Buchanan Ingersoll & Rooney PC booted from representing opponent KV Pharmaceutical Co. in the long-standing infringement suit over the attention deficit disorder drug.

On Monday, U.S. Magistrate Judge Madeline Cox Arleo granted Celgene's bid to disqualify Buchanan from the Hatch-Waxman dispute, handing the pharmaceutical giant a victory against the firm.

“The evidence thus supports the conclusion that Buchanan did not explain the material risk...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.